IMRN
Closed
Immuron Ltd Adr
1.7
0.0 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.74
Day's Range: 1.56 - 1.78
Send
sign up or login to leave a comment!
When Written:
1.87
Immuron Ltd is a biotechnology company that is focused on developing and commercializing oral immunotherapeutics for the treatment of various medical conditions. The company's lead product candidate, IMM-124E, is a proprietary polyclonal antibody therapy designed to treat Clostridium difficile infection and other gastrointestinal diseases. Immuron also has a pipeline of other product candidates in various stages of development, including IMM-529 for the treatment of Campylobacter and Helicobacter pylori infections.
Immuron is headquartered in Melbourne, Australia, and is listed on the Australian Securities Exchange (ASX: IMC) and on the NASDAQ Capital Market in the form of American Depositary Receipts (ADRs). Each ADR represents 40 ordinary shares of the company's stock. Immuron's ADRs trade under the ticker symbol IMRN. As of August 2021, the company had a market capitalization of approximately $61 million.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Immuron is headquartered in Melbourne, Australia, and is listed on the Australian Securities Exchange (ASX: IMC) and on the NASDAQ Capital Market in the form of American Depositary Receipts (ADRs). Each ADR represents 40 ordinary shares of the company's stock. Immuron's ADRs trade under the ticker symbol IMRN. As of August 2021, the company had a market capitalization of approximately $61 million.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!